Polyclonal Antibody Or Immunogloblin Of Identified Binding Specificity Patents (Class 530/389.1)
  • Publication number: 20150147274
    Abstract: Antibodies which are antagonists of the human HGF receptor (MET), wherein the antibodies specifically bind to amino acid residues 568-741 of human MET (SEQ ID No: 1) with high affinity.
    Type: Application
    Filed: November 30, 2012
    Publication date: May 28, 2015
    Inventors: Danielle Marie Di Cara, John McCafferty, Ermanno Gherardi, Anthony Richard Pope
  • Publication number: 20150139997
    Abstract: Anti-DR5 family member antibodies and bispecific antibodies comprising one or more anti-DR5 family member antibodies are disclosed. These antibodies can be used to trigger cell death on DR5 positive cells.
    Type: Application
    Filed: July 9, 2013
    Publication date: May 21, 2015
    Applicant: INTERNATIONAL - DRUG - DEVELOPMENT - BIOTECH
    Inventors: Claudine Brigitte Fernande Vermot-Desroches, Olivier Frédéric Subiger, Laurence Françoise Jeanne-Marie Bourdin
  • Publication number: 20150140005
    Abstract: There is provided a method of treating an inflammatory response to infection and complications associated therewith, by administering a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor to a subject, in need thereof. There is also provided a method of treating or preventing treating or preventing renal failure; renal dysfunction; respiratory failure; respiratory dysfunction; or acute lung injury. Provided herein are uses, pharmaceutical compositions, and commercial packages associated therewith.
    Type: Application
    Filed: May 17, 2013
    Publication date: May 21, 2015
    Inventors: Keith R. Walley, John H. Boyd, James A. Russell
  • Patent number: 9034325
    Abstract: The present invention relates to amino acid sequences that are directed against (as defined herein) multitarget scavenger receptors such as e.g. Lox-1, RAGE, CD36, SR-A1, SR-B1, galectin-1, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively).
    Type: Grant
    Filed: July 22, 2009
    Date of Patent: May 19, 2015
    Assignee: Ablynx N.V.
    Inventors: Maria Joao Saraiva, Peter Vanlandschoot, Edward Dolk, Renee de Bruin
  • Publication number: 20150133637
    Abstract: The present invention relates to biological materials against P2X7 and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit the biological activity of the P2X7 receptor, such as activation by ATP.
    Type: Application
    Filed: May 31, 2013
    Publication date: May 14, 2015
    Applicant: Ablynx N.V.
    Inventors: Welbeck Owusu Danquah, Friedrich Nolte, Catelijne Stortelers, Toon Laeremans
  • Publication number: 20150133644
    Abstract: The present invention provides improved methods for the manufacturing of IVIG products. These methods offer various advantages such as reduced loss of IgG during purification and improved quality of final products. In other aspects, the present invention provides aqueous and pharmaceutical compositions suitable for intravenous, subcutaneous, and/or intramuscular administration. In yet other embodiments, the present invention provides methods of treating a disease or condition comprising administration of an IgG composition provided herein.
    Type: Application
    Filed: June 19, 2014
    Publication date: May 14, 2015
    Inventors: Leopold Bruckschwaiger, Sonja Svatos, Julia Nuernberger, Wolfgang Teschner, Harald Arno Butterweck, Hans-Peter Schwarz, Thomas Gundinger, Bernhard Koelbl, Reinhard Grausenburger, Azra Pljevljakovic
  • Patent number: 9028818
    Abstract: The invention relates to antibodies binding to the proteins forming adrenomedullin receptors, and to the uses thereof as a drug.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: May 12, 2015
    Assignees: Universite d'Aix-Marseille, Assitance Publique Hôpitaux de Marseille
    Inventors: L'Houcine Ouafik, Kamel Mabrouk, Itidal Kaafarany, Pierre-Marie Martin
  • Publication number: 20150118235
    Abstract: An antibody that binds a MeCP2E1 isoform of MeCP2 protein, wherein the antibody comprises a region comprising the amino acid sequence of SEQ ID NO:4. A method for detecting and/or monitoring a disease or a disorder caused by an over-expression or an under-expression of a MeCP2E1 isoform of MeCP2 protein, comprising the steps of: (i) obtaining a first sample from a mammalian subject; (ii) contacting the first sample with the anti-MeCP2E1antibody; (iii) removing unbound antibody from the sample; (iv) conducting an immunoassay on the first sample to determine a first value for expression of the MeCP2E1 isoform; (v) comparing the first value to a reference value for expression of the MeCP2E1 isoform in healthy mammalian subjects; wherein a deviation of the first value from the reference value indicates the presence of a disease or a disorder caused by an over-expression or an under-expression of the MeCP2E1 isoform.
    Type: Application
    Filed: October 24, 2013
    Publication date: April 30, 2015
    Applicant: University of Manitoba
    Inventor: Mojgan Rastegar
  • Publication number: 20150118236
    Abstract: Subject of the present invention is a method for predicting the risk of getting a cardiovascular event in a female subject comprising determining the level of pro-neurotensin or fragments thereof of at least 5 amino acids in a bodily fluid obtained from said female subject; and correlating said level of pro-neurotensin or fragments thereof with the a risk for getting a cardiovascular event, wherein an elevated level is predictive for an enhanced risk of getting a cardiovascular event.
    Type: Application
    Filed: March 8, 2013
    Publication date: April 30, 2015
    Inventors: Andreas Bergmann, Olle Melander
  • Publication number: 20150118252
    Abstract: Antigen binding constructs that bind to CD3, for example antibodies, including antibody fragments (such as minibodies and cys-diabodies) that bind to CD3, are described herein. Methods of use are described herein.
    Type: Application
    Filed: June 13, 2013
    Publication date: April 30, 2015
    Inventors: David T. Ho, Tove Olafsen, Jason Romero, Christian P. Behrenbruch
  • Publication number: 20150118155
    Abstract: The present invention provides a method of diagnosing the existence or risk of hyperthyroidism in a feline comprising measuring the level of expression of one or more biomarkers selected from the group consisting of e.g., IYD, TG, SLC5A5, NIS, TPO, TSHR, DUOX1, DUOX2 (ThOX), TGFB1, CSTD, DCN and SEPP1 and the expression products thereof, in a biological sample from the feline, wherein elevated expression of the one or more biomarkers in the sample relative to a control value for expression in a sample from a normal feline or feline population, or a baseline value from the feline, indicates the existence or risk of hyperthyroidism; a method of treating a feline so diagnosed; and compositions, reagents and kits for carrying out the specified methods.
    Type: Application
    Filed: June 14, 2012
    Publication date: April 30, 2015
    Applicant: Hill's Pet Nutrition, Inc.
    Inventors: Samer Al-Murrani, Xiangming Gao
  • Publication number: 20150118230
    Abstract: The present invention relates to the pharmaceutical use of FAM19A5 involved in regulating gliogenesis, and more specifically, to the use of FAM19A5 in the prevention, diagnosis, or treatment of central nervous system injuries, degenerative brain diseases, or central nervous system diseases, FAM19A5 being spread in the neural stem cells in vertebrates and regulating gliogenesis.
    Type: Application
    Filed: February 15, 2013
    Publication date: April 30, 2015
    Inventors: Jae Young Seong, Jong Ik Hwang, Woong Sun, Eun Bee Cho, Won-Ki Kim
  • Patent number: 9017957
    Abstract: An object of the present invention is to provide an antibody that can be stably supplied and can react with prostasin under non-denaturation and denaturation conditions, and an antigen peptide for preparation of the antibody. The present invention relates to a peptide consisting of the amino acid sequence shown in SEQ ID NO: 1 or a peptide consisting of an amino acid sequence that has a deletion, a substitution, or an addition of one or several amino acids with respect to the amino acid sequence shown in SEQ ID NO: 1 and having antigenicity of prostasin. Furthermore, the present invention relates to an antibody prepared using the peptide as an antigen.
    Type: Grant
    Filed: May 1, 2007
    Date of Patent: April 28, 2015
    Assignees: Hitachi Chemical Company, Ltd., Kimio Tomita, Kenichiro Kitamura
    Inventors: Hiromi Iijima, Noriya Ohta, Kimio Tomita, Kenichiro Kitamura
  • Publication number: 20150110812
    Abstract: A method of making an antibody in plants that binds to a HER receptor is described. The antibody preferably contains sequences from trastuzumab that have been optimized for expression in plants.
    Type: Application
    Filed: December 17, 2014
    Publication date: April 23, 2015
    Inventors: Michael D. McLean, Freydoun Garabagi, J. Christopher Hall
  • Patent number: 9011856
    Abstract: Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: April 21, 2015
    Assignee: UCB Pharma S.A.
    Inventors: David G. Winkler, Jiye Shi, John Latham
  • Publication number: 20150104816
    Abstract: A marker for detecting pancreatic cancer, said marker comprising a glycoprotein C4BPA or PIGR, whereby a pancreatic cancer patient can be distinguished from a chronic pancreatitis patient or a normal subject and thus specifically diagnosed. Also, the marker is usable in monitoring the postoperative prognosis of a pancreatic cancer patient. When the aforesaid marker is used in combination with another pancreatic cancer marker such as CA19-9, furthermore, a pancreatic cancer patient can be distinguished from a chronic pancreatitis patient or a normal subject and diagnosed more specifically.
    Type: Application
    Filed: April 1, 2013
    Publication date: April 16, 2015
    Applicant: NITTO BOSEKI CO., LTD.
    Inventors: Kenta Noda, Toshihide Miura, Humio Nomura, Kazuyuki Sogawa, Mamoru Sato, Hideyuki Yoshitomi, Masaru Miyazaki
  • Patent number: 9005614
    Abstract: PRLR-specific antibodies are provided, along with pharmaceutical compositions containing such antibody, kits containing a pharmaceutical composition, and methods of preventing and treating cancer.
    Type: Grant
    Filed: November 22, 2010
    Date of Patent: April 14, 2015
    Assignees: Novartis AG, Xoma Technology Ltd.
    Inventors: Jason Damiano, Mohammad Luqman, Daniel Bedinger, Linda Masat, Amer Mirza, Genevieve Nonet
  • Patent number: 8999398
    Abstract: The invention relates to compositions and methods for treating a host infected with a pathogen. The composition comprising a population of polyclonal bispecific binding molecules that can target and eliminate a host cell infected with the pathogen. Methods for activating and arming cytotoxic immune cells with the composition for use in treating a patient infected with a pathogen are also provided.
    Type: Grant
    Filed: November 5, 2010
    Date of Patent: April 7, 2015
    Assignees: TransTarget Inc., Wayne State University
    Inventors: Lawrence Lum, Manley Huang
  • Patent number: 9000131
    Abstract: This disclosure provides antibodies that specifically bind to and typically neutralize botulinum neurotoxins (e.g., BoNT/A, BoNT/B, BoNT/E, etc.) and the epitopes bound by those antibodies. The antibodies and derivatives thereof and/or other antibodies that specifically bind to the neutralizing epitopes provided herein can be used to neutralize botulinum neurotoxin and are therefore also useful in the treatment of botulism.
    Type: Grant
    Filed: July 30, 2009
    Date of Patent: April 7, 2015
    Assignee: The Regents of the University of California
    Inventors: James D. Marks, Isin N. Geren
  • Patent number: 8999342
    Abstract: Specific binding members, particularly antibodies and fragments thereof, which bind to Fibroblast Activation Protein (FAP) are provided, particularly recognizing both human and mouse FAP. These antibodies are useful in the diagnosis and treatment of conditions associated with activated stroma, including wound healing, epithelial cancers, osteoarthritis, rheumatoid arthritis, cirrhosis and pulmonary fibrosis. The anti-FAP antibodies, variable regions or CDR domain sequences thereof, and fragments thereof may also be used in therapy in combination with chemotherapeutics, immune modulators, or anti-cancer agents and/or with other antibodies or fragments thereof. Antibodies of this type are exemplified by the novel antibodies ESC1 1 and ESC 14 whose sequences are provided herein.
    Type: Grant
    Filed: October 1, 2010
    Date of Patent: April 7, 2015
    Assignee: Ludwig Institute for Cancer Research, Ltd.
    Inventors: Christoph Renner, Eliane Fischer, Stefan Bauer, Thomas Wüest
  • Patent number: 8993727
    Abstract: Disclosed is an isolated immunoglobulin. Also disclosed are pharmaceutical compositions and medicaments comprising the immunoglobulin, isolated nucleic acid encoding it, vectors, host cells, useful in methods of making it. In some embodiments the immunoglobulin comprises one to twenty-four pharmacologically active chemical moieties conjugated thereto, such as a pharmacologically active polypeptide.
    Type: Grant
    Filed: September 22, 2011
    Date of Patent: March 31, 2015
    Assignee: Amgen Inc.
    Inventors: Kenneth W. Walker, Frederick W. Jacobsen, Taruna Arora
  • Patent number: 8992910
    Abstract: The present invention provides antibodies that bind to the IL-3 receptor alpha subunit alpha (Il3R?) chain, and compositions comprising such antibodies. The present invention provides methods for inhibiting or reducing an IL3R?-expressing cell population, the methods comprising contacting a population of IL3R?-expressing cells (e.g., cancer cells and/or cancer stem cells) with an antibody that binds to IL3R?. The present invention also provides antibody conjugates comprising an antibody that binds to an IL3R? chain linked to a cytotoxic agent or anticellular agent and compositions comprising such conjugates. The present invention also provides methods for preventing, treating and/or managing a disorder associated with IL3R?-expressing cells (e.g., a hematological cancer), the methods comprising administering to a subject in need thereof an antibody that binds to IL3R?.
    Type: Grant
    Filed: April 4, 2012
    Date of Patent: March 31, 2015
    Assignee: Steamline Therapeutics, Inc.
    Inventor: Ivan Bergstein
  • Patent number: 8992919
    Abstract: The invention provides anti-polyubiquitin antibodies and methods of using the same.
    Type: Grant
    Filed: April 14, 2011
    Date of Patent: March 31, 2015
    Assignee: Genentech, Inc.
    Inventors: Vishva Dixit, Robert F. Kelley, Marissa L. Matsumoto
  • Publication number: 20150086564
    Abstract: The present invention relates to antibodies anti-sPLA2-IIA and uses thereof.
    Type: Application
    Filed: March 22, 2013
    Publication date: March 26, 2015
    Inventors: Gerard Lambeau, Emmanuel Valentin, Melanie Rennou
  • Publication number: 20150086553
    Abstract: A polypeptide binding to Annexin A1, an antagonist against Annexin A1 including the polypeptide, an anti-Annexin A1 antibody including the polypeptide or an antigen-binding fragment thereof, and methods of preventing, treating and/or diagnosing a disease, including administering the antagonist and/or the antibody or an antigen-binding fragment thereof to a subject.
    Type: Application
    Filed: September 10, 2014
    Publication date: March 26, 2015
    Inventors: Jieun HAN, Jung Min KIM, Jae Il LEE
  • Publication number: 20150078996
    Abstract: The present invention relates to mammalian antibodies, designated 12B1 and antigen-binding portions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. Also included are chimeric, bispecific, derivatized, single chain antibodies derived from the antibodies disclosed herein. Nucleic acid molecules encoding the mammalian antibodies as well as methods of use thereof are also disclosed. Also included are pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with expression of IGf-1R.
    Type: Application
    Filed: September 19, 2014
    Publication date: March 19, 2015
    Inventors: Liliane Goetsch, David Brooks, Michael Chastain, Zhi-Qiang Zhang, Nathalie Corvaia
  • Publication number: 20150079092
    Abstract: Binding members, especially antibody molecules, for interleukin (IL)-4 receptor alpha (IL-4R?), and their therapeutic use e.g. in treating or preventing disorders associated with IL-4R?, IL-4 and/or IL-13, examples of which are asthma and COPD.
    Type: Application
    Filed: September 24, 2014
    Publication date: March 19, 2015
    Inventors: Per-Olof Fredrik Eriksson, Karin Von Wachenfeldt, Suzanne Cohen, Claire Louise Dobson, Deborah Louise Lane
  • Publication number: 20150079070
    Abstract: Provided are binding polypeptides (e.g., antibodies), and effector moiety conjugates thereof, comprising a CH1 domain (e.g., a human IgG1 CH1 domain), wherein the CH1 domain has an engineered N-linked glycosylation site at amino acid position 114, according to Kabat numbering. Also provided are nucleic acids encoding the antigen-binding polypeptides, recombinant expression vectors and host cells for making such antigen-binding polypeptides. Methods of using the antigen-binding polypeptides disclosed herein to treat disease are also provided.
    Type: Application
    Filed: March 10, 2014
    Publication date: March 19, 2015
    Applicant: Genzyme Corporation
    Inventors: Clark PAN, Huawei QIU, Pradeep DHAL, Bo CHEN, Diego GIANOLIO
  • Publication number: 20150079075
    Abstract: Provided herein are isolated human, chimeric, and humanized antibodies and antigen-binding fragments thereof that specifically bind to CD11a. Also provided are methods of treating human immunodeficiency virus (e.g., reducing the risk of developing or preventing the development of HIV infection or AIDS) in a subject that has an HIV infection or AIDS that include administering at least one of the antibodies or antigen-binding fragments to the subject. Also provided are methods of crosslinking CD11a on the surface of a cell that include contacting the cell with at least one of the antibodies or antigen-binding fragments. Also provided are compositions (e.g., pharmaceutical compositions) containing at least one of the antibodies or antigen-binding fragments.
    Type: Application
    Filed: September 13, 2012
    Publication date: March 19, 2015
    Applicant: CytoDyn Inc.
    Inventors: Richard Trauger, Robert Fleischaker
  • Publication number: 20150071911
    Abstract: The present invention is directed to the combination therapy of an afucosylated anti-CD20 antibody with a mTOR inhibitor for the treatment of cancer, especially to the combination therapy of CD20 expressing cancers with an afucosylated humanized B-Ly1 antibody and a mTOR inhibitor such as Temsirolimus or Everolimus.
    Type: Application
    Filed: March 31, 2014
    Publication date: March 12, 2015
    Applicant: ROCHE GLYCART AG
    Inventors: FRANK HERTING, CHRISTIAN KLEIN
  • Publication number: 20150074836
    Abstract: The invention concerns nucleic acids coding for mutated or truncated forms of the human parkin gene, or forms comprising multiplication of exons, and the corresponding proteins and antibodies. The invention also concerns methods and kits for identifying mutations of the parkin gene, and for studying compounds for therapeutic purposes.
    Type: Application
    Filed: August 7, 2014
    Publication date: March 12, 2015
    Applicants: Aventis Pharma S.A., Institut National de la Santé et de la Recherche Médicale
    Inventors: Alexis Brice, Christophe Lucking, Patrice Denefle
  • Patent number: 8974781
    Abstract: The present invention relates to antibodies including human antibodies and antigen-binding portions thereof that bind to P-cadherin, and that function to inhibit P-cadherin. The invention also relates to heavy and light chain immunoglobulins derived from human P-cadherin antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human P-cadherin antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions. The invention also relates to transgenic animals or plants comprising nucleic acid molecules of the present invention.
    Type: Grant
    Filed: April 4, 2011
    Date of Patent: March 10, 2015
    Assignee: Pfizer Inc.
    Inventors: Christopher Todd Bauer, Maureen Jeri Bourner, Melanie Boyle, Gerald Fries Casperson, David William Griggs, Richard David Head, William Dean Joy, Richard Allen Mazzarella, Ralph Raymond Minter, Mark Allen Moffat, Barrett Richard Thiele, Todd Lee Vanarsdale
  • Publication number: 20150064727
    Abstract: Ectoparasite infestation of a substrate like bedding is detected by contacting a sample from the substrate with a polyclonal ectoparasite antibody generated from a whole ectoparasite immunogen, under conditions wherein the antibody specifically binds ectoparasite antigen in the sample.
    Type: Application
    Filed: February 27, 2013
    Publication date: March 5, 2015
    Inventors: Rajeev Vaidyanathan, Joseph Perrone, Ellen Braulieu, Scott Fields
  • Publication number: 20150064169
    Abstract: This disclosure provides protease-regulated antibodies which specifically bind to tissue factor pathway inhibitor (TFPI). The antibodies are useful for treating bleeding disorders such as hemophilia.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 5, 2015
    Inventors: Zhuozhi Wang, Ruth Winter, John Murphy
  • Publication number: 20150065693
    Abstract: There is provided a composition for prophylaxis or treatment of vascular or valvular calcification including a dipeptidylpeptidase-4 (DPP-4) inhibitor. The DPP-4 according to one exemplary embodiment of the present disclosure is expressed at an increased level when blood vessels and valves are calcified, and the calcification decreases remarkably upon administration of the DPP-4 inhibitor. Therefore, the DPP-4 inhibitor can be useful in treatment or prophylaxis of blood vessels or valves.
    Type: Application
    Filed: August 29, 2014
    Publication date: March 5, 2015
    Inventors: Jae Kwan SONG, Eun Ju CHANG
  • Patent number: 8968750
    Abstract: The present invention relates to peptides comprising at least one antigenic determinant or epitope of an apicomplexan Ferlin, Ferlin-like protein and/or another C2-domain containing protein for use as malaria vaccines. It further relates to compositions comprising said peptides and to the use of such compositions as malaria vaccines.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: March 3, 2015
    Assignee: Ruprecht-Karls-Universität Heidelberg
    Inventors: Ann-Kristin Mueller, Eva Morath
  • Publication number: 20150050278
    Abstract: Fc domains and CH3 domains are disclosed that bind the neonatal Fc (FcRn) receptor and are at least 99% monomeric. Monomeric Fc domain molecules and CH3 domain molecules are disclosed herein that include a monomeric Fc domain or a monomeric CH3 domain and an effector molecule. In some embodiments, the monomeric Fc or monomeric CH3 domain include amino acid substitutions and/or CDR insertions in the beta strands such that they specifically bind an antigen. Methods for using these monomeric Fc domains, monomeric CH3 domains, monomeric Fc domain molecules and CH3 domain molecules are also provided.
    Type: Application
    Filed: March 14, 2013
    Publication date: February 19, 2015
    Inventors: Dimiter S. Dimitrov, Tianlei Ying
  • Publication number: 20150050268
    Abstract: Polypeptides are provided directed against IL-6R at specific dose ranges and dosing schedules that result in a prolonged effect on IL-6 mediated signaling. In particular, the invention provides pharmacologically active agents, compositions, methods and/or dosing schedules that have certain advantages compared to the agents, compositions, methods and/or dosing schedules that are currently used and/or known in the art, including the ability to dose less frequently or to administer lower doses to obtain equivalent effects in inhibiting IL-6 mediated signaling.
    Type: Application
    Filed: September 24, 2012
    Publication date: February 19, 2015
    Inventors: Josefin-Beate Holz, Stefaan Rossenu, Steven De Bruyn, Maria Laura Sargentini-Maier, Ozkan Yalkinoglu
  • Publication number: 20150040251
    Abstract: The present invention is based upon the identification of a number of antigens derived from species of the genus Teladorsagia, which can be used to raise immune responses in animals—particularly those animals susceptible or predisposed to infection by (or with) one or more Teladorsagia species. The antigens may be exploited to provide compositions and vaccines for raising protective immune responses in animals—the protective immune responses serving to reduce, prevent, treat or eliminate Teladorsagia infections/infestations.
    Type: Application
    Filed: February 4, 2013
    Publication date: February 5, 2015
    Inventors: Jacqueline Matthews, Alasdair Justice Nisbet, David Knox
  • Publication number: 20150037351
    Abstract: The present invention relates to an inhibitor of the P2Y2 receptor or an inhibitor of the P2Y2 receptor signaling pathway for use in preventing the metastasis of tumours or as a lead compound for developing a drug for preventing the metastasis of tumours.
    Type: Application
    Filed: March 21, 2013
    Publication date: February 5, 2015
    Inventors: Stefan Offermanns, Boris Strilic, Dagmar Schumacher, Nina Wettschureck
  • Publication number: 20150037328
    Abstract: The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (CXCR4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. The invention further relates to therapeutic methods for use of these antibodies and anti-CXCR4 antibody-drug conjugates for the treatment of a disorder associated with CXCR4 function or expression (e.g., cancer), such as colon, RCC, esophageal, gastric, head and neck, lung, ovarian, pancreatic cancer or hematological cancers.
    Type: Application
    Filed: August 1, 2014
    Publication date: February 5, 2015
    Inventors: Shu-Hui LIU, Flavia Mercer PERNASETTI, Wei-Hsien HO
  • Publication number: 20150030597
    Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of a KDR-1121 or DC101 antibody, an extracellular hinge domain, a T cell receptor transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.
    Type: Application
    Filed: August 8, 2014
    Publication date: January 29, 2015
    Inventors: Steven A. Rosenberg, Dhanalakshmi Chinnasamy
  • Publication number: 20150030599
    Abstract: An anti-EGFR scFV fragment, an anti-c-Met/anti-EGFR bispecific antibody including the same, and a method of preventing and/or treating a cancer using the same are provided.
    Type: Application
    Filed: July 29, 2014
    Publication date: January 29, 2015
    Inventors: Mi Young CHO, Seung Hyun Lee, Kwang Ho Cheong, Young Jun Koh, Jung Wook Lee, Powei Lin, Jae Woong Hwang
  • Patent number: 8940872
    Abstract: The present invention provides an antibody that specifically binds to an abnormal TDP-43 protein aggregate, an agent comprising the antibody for detecting a TDP-43 proteinopathy lesion, and a method for detecting or diagnosing a TDP-43 proteinopathy lesion by using the antibody.
    Type: Grant
    Filed: July 7, 2008
    Date of Patent: January 27, 2015
    Assignee: Tokyo Metropolitan Institute of Medical Science
    Inventors: Masato Hasegawa, Tetsuaki Arai, Takashi Nonaka, Fuyuki Kametani, Haruhiko Akiyama
  • Publication number: 20150024512
    Abstract: The invention relates to methods for selectively quantifying A-beta aggregates, comprising the immobilization of anti-A-beta antibodies on a substrate, application of the sample to be tested onto the substrate, addition of probes labeled for detection, which mark these by specific binding to A-beta aggregates and detection of the marked aggregates.
    Type: Application
    Filed: December 21, 2012
    Publication date: January 22, 2015
    Inventors: Dieter Willbold, Susanne Aileen Funke, Lei Wang-Dietrich, Eva Birkmann, Oliver Bannach
  • Publication number: 20150018241
    Abstract: Herein is reported the use of an immobilized non-covalent complex of a neonatal Fc receptor (FcRn) and beta-2-microglobulin (b2m) as affinity chromatography ligand in general and, for example, for the determination of the in vivo half-live of an antibody by determining the ratio of the retention times of the antibody and a reference antibody.
    Type: Application
    Filed: February 14, 2013
    Publication date: January 15, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Roberto Falkenstein, Hubert Hertenberger, Petra Rueger, Tilman Schlothauer
  • Publication number: 20150018531
    Abstract: Novel modulators, including antibodies and derivatives thereof, and methods of using such modulators to treat proliferative disorders are provided.
    Type: Application
    Filed: February 22, 2013
    Publication date: January 15, 2015
    Applicant: STEM CENTRX, INC.
    Inventors: Laura Saunders, Scott J. Dylla, Orit Foord, Robert A. Stull, Michael Torgov, Hui Shao, David Liu
  • Publication number: 20150018532
    Abstract: The invention relates to antibodies to Aspergillus species and to methods of producing those antibodies. The invention also relates to the use of such antibodies in identifying the presence of the Aspergillus species and to methods of treating an infection with the Aspergillus species.
    Type: Application
    Filed: June 6, 2014
    Publication date: January 15, 2015
    Applicant: UNIVERSITY OF EXETER
    Inventor: Christopher THORNTON
  • Patent number: 8927225
    Abstract: Disclosed is an assay (method) to quantify the amounts of catecholamine-O-methyltransferase (COMT) protein in samples, such as extracts from cell cultures, body fluids, tissues, and environmental samples. It uses novel agents (anti-NE, COMT-NE, or COMT-epitope-NE) in combination with two previously described agents (anti-COMT and COMT) in a competitive ELISA system to achieve this aim.
    Type: Grant
    Filed: September 8, 2009
    Date of Patent: January 6, 2015
    Assignee: The University of Hong Kong
    Inventors: Shu Leong Ho, Wing Lok Ho, David Boyer Ramsden
  • Publication number: 20150005476
    Abstract: The invention relates to a process for enriching IgA (and IgM) from IgA-comprising material. In particular, it relates to a sequential elution process of an anion exchanger that leads to an advantageous enrichment and separation of monomeric and dimeric IgA.
    Type: Application
    Filed: March 8, 2013
    Publication date: January 1, 2015
    Applicant: CSL Behring AG
    Inventors: Ibrahim El Menyawi, Marius Loetscher, Doreen Siegemund